Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: Gynecol Oncol. 2012 Aug 29;127(3):544–551. doi: 10.1016/j.ygyno.2012.08.031

Endometrial cancer (EC) risk-reducing practices in a longitudinal cohort of women before and after genetic testing for Lynch syndrome. (A) Overall percentage of subjects engaging in EC risk-reductiona at baseline and one yearb after genetic testing. (B) Cumulative rates of prophylactic hysterectomy (PH) at baseline and at one- and three-year follow-up. (C) Rates of annual EC surveillance at baseline and at one-year follow-up.

^a “Engaging in EC risk-reduction” defined as either (1) having had a PH, (2) reporting annual EC surveillance by transvaginal ultrasound and/or endometrial biopsy, and/or (3) age <35 years old.

^b Uptake in EC risk-reduction at one-year follow-up is not reported for subjects found to have “true negative” genetic test results, since they would no longer be considered at risk for Lynch-associated EC.

Endometrial cancer (EC) risk-reducing practices in a longitudinal cohort of women before and after genetic testing for Lynch syndrome. (A) Overall percentage of subjects engaging in EC risk-reductiona at baseline and one yearb after genetic testing. (B) Cumulative rates of prophylactic hysterectomy (PH) at baseline and at one- and three-year follow-up. (C) Rates of annual EC surveillance at baseline and at one-year follow-up.

^a “Engaging in EC risk-reduction” defined as either (1) having had a PH, (2) reporting annual EC surveillance by transvaginal ultrasound and/or endometrial biopsy, and/or (3) age <35 years old.

^b Uptake in EC risk-reduction at one-year follow-up is not reported for subjects found to have “true negative” genetic test results, since they would no longer be considered at risk for Lynch-associated EC.